T cell therapy developer Crescendo Biologics Ltd (Crescendo) has named Eva-Lotta Allan Non-Executive Director of the company. The former CFO of Immunocore brings in over 30 years’ experience in the biopharmaceutical industry, with special expertise in strategic partnerships with Big Pharma. The Board member of the British Industry Organisation (BIA) is currently a non-executive director for cancer immunotherapy specialist Targovax ASA which recently announced new patents for its colon cancer RAS-targeting candidate drug TG02. Prior to Immunocore, Eva-Lotta was Chief Business Officer at Ablynx NV.
Houston, TX – (EmailWire) — The Biotech Times™ aggregates, publishes and distributes news about the Biotech Industry. In association with EmailWire™, The Biotech Times, helps businesses and organizations in the industry with press release distribution. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us through the following messaging apps:
